Datapoint: Lilly Scores UC Nod for Omvoh

November 1

After a long wait and previous rejection, the FDA on Oct. 26 approved Lilly’s Omvoh for the treatment of moderately to severely active ulcerative colitis (UC) in adults. The drug is the first interleukin-23p19 (IL-23p19) antagonist approved to treat UC, and is first administered via infusions, then self-injections as maintenance requires. Among the most advantaged ulcerative colitis therapies covered under the medical benefit are tumor necrosis factor-alpha blockers, such as Johnson & Johnson’s Remicade, which holds covered or better status for 94% of insured lives, Merck’s Remicade biosimilar Renflexis (92%) and Pfizer’s Remicade biosimilar Inflectra (91%).

SOURCE: MMIT Analytics, as of 10/30/23